Skip to main content
Abdeckung

All News Items

 

FyoniBio collaborates with BioLamina and Alder Therapeutics

08.02.2024 / FyoniBio, a contract development organization (CDO) specializing in customized cell line and process development has partnered with BioLamina, a biotech company renowned for its expertise in extracellular laminin-based cell biology and development of laminins as tools for cell culture, and Alder Therapeutics, a virtual preclinical allogeneic stem cell therapy development company. The consortium will advance the development of laminins for clinical applications. … more

Pain and touch sensations require Schwann cells

07.02.2024 / Special receptor cells under the skin enable us to feel pain and touch. But Schwann cells also play a key role in detecting such stimuli, researchers at the Max Delbrück Center report in “Nature Communications.” This discovery opens new avenues for pain therapy. … more

Gene editing precisely repairs immune cells

05.02.2024 / Some hereditary genetic defects cause an exaggerated immune response that can be fatal. Using the CRISPR-Cas9 gene-editing tool, such defects can be corrected, thus normalizing the immune response, as researchers led by Klaus Rajewsky from the Max Delbrück Center now report in “Science Immunology.” … more

Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177

31.01.2024 / Eckert & Ziegler's supply of Lu-177 and Ac-225 enables Nucleus Radiopharma entering a new era in cancer care … more

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

23.01.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access to Eckert & Ziegler's high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals. … more

Third ERC Grant for Gaetano Gargiulo

18.01.2024 / Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant. … more

"More Entrepreneurial Thinking in Research"

12.01.2024 / Interview with Professor Maike Sander, Scientific Director of the Max Delbrück Center … more

Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates

08.01.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Eckert & Ziegler will support ARTBIO to establish manufacturing and delivery of its pipeline therapies using its proprietary AlphaDirectTM Lead-212 (Pb-212) isolation technology. … more

New agent regulates serotonin production

27.12.2023 / Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market. … more

A neuromuscular model for drug development

19.12.2023 / In neuromuscular diseases, neurons and muscle cells stop communicating properly. Researchers led by Mina Gouti can now model this in 2D in a culture dish. Writing about their findings in “Nature Communications”, they say the new model promises to revolutionize high-throughput drug screening studies. … more

Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

15.12.2023 / CELLphenomics’ PD3D® tumor model platform will expand Charles River’s portfolio of 3D in vitro testing services … more

Berlin Cures advances fight against Long COVID on a pan-European level

14.12.2023 / Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is expanding its Phase II clinical trial into a pan-European, multi-center collaboration in the fight against Long COVID. A total of 12 sites in Germany, Austria, Switzerland, Finland and Spain are working to advance clinical research into this escalating global health problem. Additional trial sites in Switzerland, Spain and Germany are expected to soon follow. First results of the Phase II trial are expected in 2024. In the event of positive results, Berlin Cures is aiming for a larger Phase III study, which is a prerequisite for the approval of BC 007. … more

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform

11.12.2023 / Glycotope GmbH (Glycotope) has signed an agreement with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec. … more

What do scientists actually do in the lab?

30.11.2023 / Grizzly bears in hibernation or a pineapple in an MRI scanner – at the “Science Day” at the “Robert Havemann” high school in Berlin-Karow, researchers from the Max Delbrück Center presented students of grades 11 and 12 unusual facets of their research. … more

A new hub for cutting-edge cancer care

25.11.2023 / From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research. … more

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)

23.11.2023 / Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University Hospital in Essen, Germany. … more

Personnel Changes in the Management of Eckert & Ziegler AG

22.11.2023 / Changes in the Executive Board and Supervisory Board … more

Heart repair via neuroimmune crosstalk

17.11.2023 / Unlike humans, zebrafish can completely regenerate their hearts after injury. They owe this ability to the interaction between their nervous and immune systems, as researchers led by Suphansa Sawamiphak from the Max Delbrück Center now report in the journal “Developmental Cell.” … more

Lisec-Artz Prize goes to Simon Haas

15.11.2023 / Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers. … more

Influential in their field

15.11.2023 / Sofia Forslund, Friedemann Paul, and Nikolaus Rajewsky are among the Highly Cited Researchers 2023. Each year the company Clarivate compiles a "Who's Who" list of highly influential researchers. … more

Eckert & Ziegler Establishess German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

14.11.2023 / Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). … more

Eckert & Ziegler Establishess German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

14.11.2023 / Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). … more

Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023

14.11.2023 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month result was around € 2 million higher than the previous year's figure. In addition, there was an increase in expenses for future projects in the field of nuclear medicine diagnostics and therapy. … more

Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules

01.11.2023 / Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital. Seed financing will drive commercial growth for Cambrium’s first product, NovaColl™, and accelerate expansion into new industries … more

Controlling organoids with light

30.10.2023 / Organoids help researchers understand biological processes in health and in disease. It is, however, difficult to influence the way in which they organize themselves into complex tissues. Now a group led by Nikolaus Rajewsky has found a new way to do so. They report their work in Nature Methods. … more

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

23.10.2023 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-177. … more

Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets

20.10.2023 / The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. A separate decision will be taken at a later date on the specific start and the manner of the exit. In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. PTX also includes Myelo Therapeutics GmbH. … more

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

17.10.2023 / LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement. … more

Mutation puts women at higher risk of heart failure

16.10.2023 / When the PRDM16 gene mutates, heart muscle cells undergo changes in their metabolism. This increases the risk of congenital heart failure in women more than men, as a ECRC research team led by Sabine Klaassen and Jirko Kühnisch reports in “Cardiovascular Research.” … more

Boost for Berlin’s biotech sector

11.10.2023 / Campus Berlin-Buch has a new start-up center: The BerlinBioCube was ceremonially opened on October 11, 2023 in the presence of the Governing Mayor. … more

Why research needs diversity

11.10.2023 / A data gap that threatens timely diagnosis and treatment for half the population, the visibility of female researchers in Wikipedia, and myriads of microbes in and on our bodies – the Max Delbrück Center's program for the Berlin Science Week 2023 is focused on dimensions of diversity. … more

Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225

10.10.2023 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225 (Ac-225). Under the terms of the agreement, PharmaLogic will have access to Eckert & Ziegler's high-purity, non-carrier-added Actinium-225 for the labeling of radiopharmaceuticals for research and development work and commercial use. … more

Avatars to help tailor glioblastoma therapies

04.10.2023 / Scientists have created a new zebrafish xenograft platform to screen for novel treatments for an aggressive brain tumor called glioblastoma, according to a new study by the Gerhardt and De Smet labs published in “EMBO Molecular Medicine.” … more

Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma

26.09.2023 / Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million. … more

Starting up with highly promising immunotherapies

22.09.2023 / After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable. … more

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

13.09.2023 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as BioGuides, that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor cancers. … more

The thrill of science

11.09.2023 / Young students are fascinated by the experiments they can participate in at the Gläsernes Labor (Life Science Learning Lab). Thanks to a special fundraiser, socially disadvantaged children from the district of Marzahn-Mitte were able to don lab coats and carry out some thrilling research. … more

"Drivers for Germany's Future Sustainability"

07.09.2023 / The UNIPRENEURS Initiative has recognized the entrepreneurial spirit of 20 professors, among them ECRC researcher Simone Spuler. As a co-founder of the startup MyoPax, she is pioneering stem cell technology to develop regenerative therapies for previously incurable muscle diseases. … more

ERC Starting Grant awarded to Fabian Coscia

05.09.2023 / Whether aggressive cancer cells can spread unchecked depends, to no small degree, on their cellular neighborhood. Fabian Coscia wants to analyze exactly what happens at the proteome level during this interaction. He has now been selected for a €1 million-plus grant from the European Research Council (ERC) to pursue this research. … more

The Max Delbrück Center celebrates 15 years of MDC‑BIMSB

05.09.2023 / Internationally renowned for pioneering achievements and geared to inter-institutional cooperation: 22 research groups at the Berlin Institute for Medical Systems Biology in the Max Delbrück Center (MDC-BIMSB) explore how genes regulate life. It is now celebrating its 15th birthday. … more

Rare kidney disease is genetically decoded

23.08.2023 / Bartter syndrome type 3 is the result of several structural variants in the genome. By using long-read sequencing, Janine Altmüller and her team from the Max Delbrück Center, the BIH and University Hospital Cologne mapped out the rare disease in unprecedented detail. They have now reported their findings in “Genome Medicine.” … more

Deficiency in certain brain proteins promotes compulsive behavior

22.08.2023 / Our behavior is controlled through neural circuits in the brain. Molecular disturbances can lead to stereotypical behavior, as seen in neuropsychiatric disorders like obsessive-compulsive and autism spectrum disorders. A research team has now demonstrated that the absence of two proteins, Intersectin1 and Intersectin2, in mice leads to disrupted neural signaling and compulsive repetitive behavior, which is also observed in patients with Intersectin1 mutations. This supports the idea that such defects can cause neuropsychiatric diseases. The study is published in “Proceedings of the National Academy of Sciences“. … more

Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

10.08.2023 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023. At € 10.9 million or € 0.52 per share, net income was € 3.5 million or 25% lower than in the same period last year. Currency effects in particular reduced the result by around € 2.0 million compared with the previous year. Moreover, increased expenses for future projects in the field of diagnostics and therapy in nuclear medicine had an additional impact. … more

Came to stay: How the herpes virus HCMV deceives its host cells

08.08.2023 / Once infected - always infected: Herpes viruses lie dormant in the body and can be reactivated by certain circumstances. The herpes virus HCMV is particularly widespread, yet despite its impact, well-tolerated and effective antiviral drugs or vaccinations do not exist. However, a team of researchers from FMP and Charité has now found out a lot about the interaction between HCMV and its host cells, which could also be useful for the development of antiviral agents. The paper has just been published in the journal „Nature Microbiology“. … more

New muscle therapy gets fast-track boost

26.07.2023 / The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall. … more

Low binding affinity improves vaccine efficacy

24.07.2023 / Researchers at BIH and the Max Delbrück Center have developed a new approach for vaccines against coronaviruses using modified spike proteins with lower binding affinity. This method could make vaccinations more effective, the team writes in the "European Journal of Immunology". … more

How rhomboid protease activity is regulated

23.07.2023 / Rhomboid proteases are a promising target for new drugs. Now researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) have uncovered a mechanism for regulating enzyme activity. The key role is played by dynamics of the gate discovered a few years ago, which opens briefly when other proteins are cleaved. The results, based on various experimental and theoretical methods, have just been published in the Science Advances journal. … more

A potential new biomarker for Alzheimer’s

20.07.2023 / The Arl8b protein provides new insights into the mechanisms underlying Alzheimer’s disease. It also has the potential to function as a diagnostic marker. The scientists behind this discovery, a team led by Erich Wanker from the Max Delbrück Center, have published their findings in “Genome Medicine”. … more

Only long-living RNAs reach their destination

18.07.2023 / RNA molecules travel long distances through nerve cells. To reach their destination, they need one thing more than any other – a long life – as a research team led by Marina Chekulaeva from MDC-BIMSB reports in the journal “Molecular Cell.” … more

Kalender Icon

Events

all events
Kalender Icon
Kalender Icon
Kalender Icon

22.03.2024, 09:00-
22.03.2024, 14:00
UniStem Day 2024